The global Iron Deficiency Anemia (IDA) therapy market was valued at USD 4.5 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 7.6% from 2024 to 2031, reaching an estimated market value of USD 7 billion by the end of the forecast period. IDA remains one of the most common nutritional disorders worldwide, affecting a significant proportion of the global population, especially women and children. The rising prevalence of iron deficiency anemia, coupled with an increased focus on healthcare expenditure, is fueling the growth of this market.
As the market continues to evolve, technological advancements in treatment options, along with growing awareness and access to healthcare, are expected to further propel the demand for iron deficiency anemia therapies. The increasing focus on effective and accessible treatment options for both mild and severe cases of IDA is expected to be a major driver of market expansion in the coming years.
Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/34729
Key Industry Highlights
Iron Deficiency Anemia therapy market growth is largely driven by the growing prevalence of IDA across different demographic groups, particularly among women of childbearing age, pregnant women, and individuals with chronic conditions such as chronic kidney disease. Oral iron therapy remains the most common and affordable treatment option. However, intravenous iron therapies, particularly high-dose formulations like Ferumoxytol (Feraheme), have gained popularity due to their rapid effectiveness and reduced gastrointestinal side effects.
In June 2021, Sandoz launched a generic version of Ferumoxytol, expanding treatment options for patients with chronic kidney disease or those unable to tolerate oral iron supplements. Furthermore, North America is expected to continue dominating the market, driven by a high prevalence of iron deficiency anemia, advanced healthcare infrastructure, and the presence of leading pharmaceutical players.
Market Dynamics
Driver:
The increasing prevalence of iron deficiency anemia is one of the primary drivers for market growth. Poor dietary habits, inadequate absorption of iron due to gastrointestinal issues, and the aging population are significant contributing factors. Chronic diseases such as chronic kidney disease, which often results in reduced iron absorption, are also driving demand for more effective therapies. The expanding elderly population, who are more susceptible to anemia due to age-related physiological changes, is anticipated to further boost market growth.
Restraint:
One of the key restraints for the market is the high cost of advanced therapies, particularly intravenous iron treatments. This can limit access to these therapies in low-income and developing regions. Furthermore, the lack of skilled healthcare professionals in emerging markets poses a challenge to the effective treatment and management of iron deficiency anemia.
Opportunity:
Emerging markets, particularly in Asia Pacific, Latin America, and the Middle East, present lucrative opportunities for growth. These regions are witnessing increasing healthcare expenditure and rising awareness about iron deficiency anemia, creating a robust demand for effective treatment options. Additionally, ongoing advancements in intravenous iron therapy, such as new formulations that improve efficacy and reduce side effects, provide significant growth opportunities for market players.
Category-wise Analysis
Oral iron supplements are currently the most widely used treatment for iron deficiency anemia due to their affordability and ease of use. However, intravenous iron therapy is gaining significant traction, especially in patients who cannot tolerate oral iron or in cases of severe anemia. Parenteral iron therapy, which includes options like Sodium Ferric Gluconate, Iron Carbohydrates, and Ferric Hydroxide, is expected to dominate the market, holding a share of over 60% in 2024.
The adult segment is projected to account for 63.4% of the market share in 2024. This is primarily due to the high prevalence of IDA among adult women, particularly those in their reproductive years, as well as individuals suffering from chronic diseases. Additionally, the growing geriatric population, who are at an increased risk of iron deficiency anemia, is expected to contribute significantly to the market’s growth.
Regional Insights
North America is anticipated to remain the largest market for iron deficiency anemia therapies, accounting for 36.56% of the global market share in 2024. The U.S. is the dominant player in this region, thanks to its well-established healthcare infrastructure, high healthcare spending, and the growing prevalence of iron deficiency anemia, particularly among older adults.
Europe also holds a significant share of the market, with countries like Germany, France, and the U.K. experiencing high demand for both oral and intravenous iron therapies. The Asia Pacific region, however, is expected to witness the fastest growth due to a large population base, rising health awareness, and an increasing elderly demographic in countries like China and India.
Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/34729
Competitive Landscape
The iron deficiency anemia therapy market is highly competitive, with several leading pharmaceutical companies and emerging players involved in the development of new treatment options. Key strategies employed by market leaders include the development of novel formulations, expansion of distribution networks, and collaborations with healthcare providers.
Some of the major companies in the market include Akebia Therapeutics, Bayer AG, Pharmacosmos A/S, Sanofi, Johnson & Johnson, CSL Vifor, and AbbVie Inc. These companies are focusing on innovation in both oral and intravenous iron therapies, along with ongoing research to enhance treatment efficacy and minimize side effects. Furthermore, collaborations and partnerships with hospitals, clinics, and diagnostic centers are helping these companies expand their market presence.
Key Players
Akebia Therapeutics, Inc.
Bayer AG
Pharmacosmos A/S
Sanofi
Johnson & Johnson Services, Inc.
CSL Vifor
AbbVie Inc.
Novartis AG
Teoxane
GSK plc
AdvaCare Pharma
Apotex Inc.
Covis Pharma GmbH
These companies are actively involved in research and development to bring new and improved therapies to market. They are also focusing on expanding their global footprint, particularly in emerging markets, where the incidence of iron deficiency anemia is rising.
Market Segmentation
The iron deficiency anemia therapy market can be segmented by product type, treatment type, patient demographic, and region.
By Product Type:
Oral Iron Therapy
Intravenous Iron Therapy (Parenteral)
Combination Therapy
By Treatment Type:
Oral Iron Supplements (Ferrous Sulfate, Ferrous Gluconate, Ferrous Fumarate)
Intravenous Iron Supplements (Sodium Ferric Gluconate, Iron Carbohydrates, Ferric Hydroxide)
By Patient Demographic:
Adults
Children
Pregnant Women
By Region:
North America
Europe
Asia Pacific
Latin America
Middle East & Africa
Recent Developments
Recent developments in the Iron Deficiency Anemia Therapy market reflect a focus on improving the effectiveness, safety, and patient adherence to treatment. Notable milestones include:
March 2024: Cadila Pharmaceuticals launched a new iron supplement injection to treat iron deficiency anemia.
May 2021: American Regent, Inc. received FDA approval for a 1000 mg dose of Injectafer (ferric carboxymaltose injection) to treat iron deficiency anemia in adults.
June 2021: Sandoz launched a generic version of Feraheme (Ferumoxytol) to treat IDA in patients with chronic kidney disease or intolerance to oral iron supplements.
Future Outlook
The future of the iron deficiency anemia therapy market appears promising, with significant opportunities for growth driven by increasing demand for innovative therapies, expanding healthcare access in emerging markets, and ongoing advancements in treatment formulations. Personalized medicine and more effective iron supplementation methods are expected to play a key role in shaping the future landscape of the market.
As the global prevalence of iron deficiency anemia continues to rise, market players will likely focus on providing more tailored treatment options to address the needs of diverse patient populations, improving adherence to treatment regimens, and reducing healthcare costs. The development of new iron replacement therapies that minimize side effects and improve patient outcomes is set to revolutionize the management of this widespread condition in the coming years.
